Davies FE - Search Results

1

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study.

Cook G, Royle KL, Pawlyn C, Hockaday A, Shah V, Kaiser MF, Brown SR, Gregory WM, Child JA, Davies FE, Morgan GJ, Cairns DA, Jackson GH. Cook G, et al. Among authors: davies fe. Lancet Haematol. 2019 Mar;6(3):e154-e166. doi: 10.1016/S2352-3026(18)30220-5. Epub 2019 Feb 6. Lancet Haematol. 2019. PMID: 30738834 Free PMC article. Clinical Trial.

2

Detection and quantitation of the CBFbeta/MYH11 transcripts associated with the inv(16) in presentation and follow-up samples from patients with AML.

Evans PA, Short MA, Jack AS, Norfolk DR, Child JA, Shiach CR, Davies F, Tobal K, Liu Yin JA, Morgan GJ. Evans PA, et al. Leukemia. 1997 Mar;11(3):364-9. doi: 10.1038/sj.leu.2400578. Leukemia. 1997. PMID: 9067575

3

Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage.

Rawstron AC, Owen RG, Davies FE, Johnson RJ, Jones RA, Richards SJ, Evans PA, Child JA, Smith GM, Jack AS, Morgan GJ. Rawstron AC, et al. Among authors: davies fe. Br J Haematol. 1997 Apr;97(1):46-55. doi: 10.1046/j.1365-2141.1997.72653.x. Br J Haematol. 1997. PMID: 9136941 Free article.

4

p53 gene mutations in multiple myeloma.

Owen RG, Davis SA, Randerson J, Rawstron AC, Davies F, Child JA, Jack AS, Morgan GJ. Owen RG, et al. Mol Pathol. 1997 Feb;50(1):18-20. doi: 10.1136/mp.50.1.18. Mol Pathol. 1997. PMID: 9208809 Free PMC article.

5

The use of biological variables to predict outcome in multiple myeloma.

Davies FE, Jack AS, Morgan GJ. Davies FE, et al. Br J Haematol. 1997 Dec;99(4):719-25. Br J Haematol. 1997. PMID: 9432013 Free article. Review. No abstract available.

6

B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors.

Rawstron AC, Davies FE, Owen RG, English A, Pratt G, Child JA, Jack AS, Morgan GJ. Rawstron AC, et al. Among authors: davies fe. Br J Haematol. 1998 Jan;100(1):176-83. doi: 10.1046/j.1365-2141.1998.00525.x. Br J Haematol. 1998. PMID: 9450807 Free article.

7

Trisomy 12 is seen within a specific subtype of B-cell chronic lymphoproliferative disease affecting the peripheral blood/bone marrow and co-segregates with elevated expression of CD11a.

Su'ut L, O'Connor SJ, Richards SJ, Jones RA, Roberts BE, Davies FE, Fegan CD, Jack AS, Morgan GJ. Su'ut L, et al. Among authors: davies fe. Br J Haematol. 1998 Apr;101(1):165-70. doi: 10.1046/j.1365-2141.1998.00661.x. Br J Haematol. 1998. PMID: 9576197 Free article.

8

True spectrum of 14q32 translocations in multiple myeloma.

Pratt G, Fenton JA, Proffitt JA, Rawstron AC, Davies FE, Child JA, Morgan GJ. Pratt G, et al. Among authors: davies fe. Br J Haematol. 1998 Dec;103(4):1209-10. doi: 10.1046/j.1365-2141.1998.1161d.x. Br J Haematol. 1998. PMID: 9886346 Free article. No abstract available.

9

Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression.

Rawstron A, Barrans S, Blythe D, Davies F, English A, Pratt G, Child A, Morgan G, Jack A. Rawstron A, et al. Br J Haematol. 1999 Jan;104(1):138-43. doi: 10.1046/j.1365-2141.1999.01134.x. Br J Haematol. 1999. PMID: 10027726 Free article.

10

Liposomal daunorubicin: in vitro and in vivo efficacy in multiple myeloma.

Pratt G, Wiles ME, Rawstron AC, Davies FE, Fenton JA, Proffitt JA, Child JA, Smith GM, Morgan GJ. Pratt G, et al. Among authors: davies fe. Hematol Oncol. 1998 Jun;16(2):47-55. doi: 10.1002/(sici)1099-1069(199806)16:2<47::aid-hon622>3.0.co;2-3. Hematol Oncol. 1998. PMID: 10065112

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

367 results

Search Page

Filters